ConforMIS v. DePuy Synthes — 7-Patent Knee Implant Dispute Dismissed With Prejudice
ConforMIS, Inc. brought a seven-patent infringement action against DePuy Synthes and two affiliates in Delaware, targeting the TRUMATCH Personalized Solutions System, SIGMA, and ATTUNE Total Knee Implants. After roughly 2.7 years of litigation, the parties jointly stipulated to dismissal with prejudice under Fed. R. Civ. P. 41(a)(1)(A)(ii), each side bearing its own legal costs.
Seven-patent orthopedic IP dispute ends by stipulation in Delaware
ConforMIS, Inc., a medical device company specialising in patient-specific joint replacement implants, filed suit on 30 April 2021 in the Delaware District Court against DePuy Synthes, Inc., DePuy Synthes Products, Inc., and DePuy Synthes Sales, Inc. — all entities within the Johnson & Johnson orthopedic franchise. The complaint asserted infringement of seven issued US patents: US8377129B2, US9326780B2, US9186161B2, US9295482B2, US8083745B2, US8460304B2, and US8623026B2. The accused products were DePuy’s TRUMATCH Personalized Solutions System, SIGMA Total Knee Implants, and ATTUNE Total Knee Implants.
The case closed on 4 January 2024 when the parties filed a joint stipulation of dismissal with prejudice pursuant to Fed. R. Civ. P. 41(a)(1)(A)(ii). All claims, counterclaims, and affirmative defenses were dismissed, with each side absorbing its own costs, expenses, and attorney’s fees. A dismissal with prejudice is a final adjudication on the merits under US procedural law, meaning ConforMIS is permanently barred from reasserting the same patent claims against the same DePuy Synthes entities in any future action.
The case ran for approximately 975 days — consistent with complex multi-patent litigation in Delaware, though the stipulated resolution suggests the parties reached an off-record accommodation before trial. The equal-costs arrangement is notable given the breadth of the seven-patent portfolio asserted; it may suggest a negotiated settlement or cross-licensing agreement, though the public record is silent on any financial terms. No trial date or jury verdict is recorded, and the specific terms that prompted the agreed dismissal remain confidential.
Filing to filing in 979 days
Duration: ~975 days from filing to closure
Full party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | ConforMIS, Inc. | Company | Patient-specific orthopedic implant developer — holder of US8377129B2 and 6 related patentsSearch in Eureka ↗ |
| Defendant | DePuy Synthes, Inc. | Company | DePuy Synthes, Inc. and affiliates — Johnson & Johnson orthopedic device divisionSearch in Eureka ↗ |
| Plaintiff counsel | Karen L. Pascale | Attorney | Counsel for ConforMIS, Inc.Search in Eureka ↗ |
| Defendant counsel | Abigail Leigh Sellers | Attorney | Counsel for DePuy Synthes, Inc.Search in Eureka ↗ |
| Defendant counsel | Kelly E. Farnan | Attorney | Counsel for DePuy Synthes, Inc.Search in Eureka ↗ |
| Defendant counsel | Lisa S. Glasser | Attorney | Counsel for DePuy Synthes, Inc.Search in Eureka ↗ |
| Defendant counsel | Sara M. Metzler | Attorney | Counsel for DePuy Synthes, Inc.Search in Eureka ↗ |
| Defendant counsel | Valerie A. Caras | Attorney | Counsel for DePuy Synthes, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Unassigned | Chief Judge | Delaware District Court — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
The stipulation’s language — ‘dismissal with prejudice of the above-captioned action, including all claims, counterclaims, and affirmative defenses’ — is deliberately comprehensive, closing off every procedural avenue between these specific parties. The explicit inclusion of counterclaims and affirmative defenses suggests DePuy Synthes had filed responsive pleadings, potentially including invalidity challenges, which are also extinguished. The public record discloses no financial consideration, leaving the commercial terms of any underlying resolution entirely confidential.
US8377129B2 and six further patents — patient-specific orthopedic implant technology
The seven patents asserted by ConforMIS — spanning application numbers from US12/048764 through US14/148067 — collectively cover patient-specific orthopedic implant design, manufacture, and surgical instrumentation. This portfolio sits at the intersection of medical imaging, computational anatomy modelling, and precision implant fabrication. ConforMIS built its commercial identity around converting CT or MRI data into individually manufactured knee components, and these patents represent the technical core of that approach. The application filing dates span from approximately 2008 to 2014, placing them within the formative period of personalised implant commercialisation.
The strategic significance of this portfolio extends beyond the ConforMIS–DePuy Synthes dispute. As major orthopedic OEMs — including Stryker, Zimmer Biomet, and Smith & Nephew — have invested heavily in personalised and digitally planned implant systems, the claim scope of these patents becomes a sector-wide concern. The fact that even conventional total knee platforms (SIGMA, ATTUNE) were named as accused products suggests ConforMIS interprets certain claims broadly enough to reach non-bespoke systems, amplifying the FTO risk for any developer in the total knee replacement market.
Should your team run an FTO against ConforMIS’s seven-patent portfolio?
Any company developing or commercialising total knee replacement systems — whether patient-specific or conventional — should evaluate exposure against this portfolio. The inclusion of SIGMA and ATTUNE as accused products in this case suggests ConforMIS’s claim interpretation is not limited to fully customised implant workflows. R&D teams building digital surgical planning tools, patient-matched instrumentation, or image-derived implant sizing systems face the most direct overlap, but standard TKR developers should not self-exclude without a formal claim-level review.
PatSnap Eureka’s FTO Search Agent can map your product’s technical features against the independent claims of all seven ConforMIS patents, flagging potential overlap and identifying relevant prior art that could support design-around or validity challenge strategies. Claim monitoring tools allow your team to track any continuation or divisional applications that may extend this family’s reach, ensuring you receive alerts before a new related patent issues and creates fresh litigation exposure.
Run a freedom-to-operate analysis on US8377129B2 to assess your product’s exposure
Run FTO in Eureka →Similar patent litigation in the orthopedic implant and personalised surgical device sector
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this case signals for the orthopedic implant IP landscape
A seven-patent stipulated dismissal against J&J’s orthopedic division carries enforcement and FTO implications across the personalised implant sector.
ConforMIS’s patient-specific IP portfolio remains active enforcement leverage
The with-prejudice dismissal resolves only the DePuy Synthes dispute. All seven patents remain in force and available for assertion against other orthopedic competitors developing personalised or image-guided implant systems. Companies in this space — particularly those with TRUMATCH-analogous workflows — should treat this portfolio as a live threat.
Delaware remains the dominant venue for orthopedic patent disputes
Filing in the Delaware District Court is a consistent strategic choice for medical device IP plaintiffs. Delaware’s experienced patent judiciary, predictable case management, and receptiveness to complex multi-patent complaints make it a preferred forum. In-house teams at orthopedic companies should assume Delaware exposure when evaluating litigation risk.
ConforMIS v DePuy — key questions answered
The case was dismissed with prejudice by joint stipulation under Fed. R. Civ. P. 41(a)(1)(A)(ii) on 4 January 2024. All claims, counterclaims, and affirmative defenses were terminated, with each party bearing its own costs. The dismissal with prejudice bars ConforMIS from refiling the same patent claims against the same DePuy Synthes entities.
ConforMIS asserted seven US patents: US8377129B2, US9326780B2, US9186161B2, US9295482B2, US8083745B2, US8460304B2, and US8623026B2. The patents collectively cover patient-specific orthopedic implant design and surgical instrumentation technology derived from medical imaging data.
The accused products were DePuy Synthes’s TRUMATCH Personalized Solutions System, SIGMA Total Knee Implants, and ATTUNE Total Knee Implants, as well as shoulder systems. Notably, SIGMA and ATTUNE are conventional (non-personalised) total knee platforms, suggesting ConforMIS interpreted its patent claims broadly.
No. A stipulated dismissal with prejudice resolves litigation between these specific parties but does not constitute a ruling on patent validity. All seven ConforMIS patents remain issued and enforceable against third parties. Competitors in the orthopedic implant sector should treat the portfolio as active enforcement risk.
The public record does not disclose the terms of any underlying agreement. The symmetric cost allocation and use of a bilateral stipulation under Rule 41(a)(1)(A)(ii) are consistent with a negotiated resolution — potentially a licensing agreement or cross-license — rather than an outright capitulation by either side. The specific commercial terms remain confidential.
PatSnap Eureka searches patents and litigation data to answer instantly.